Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Chinese approval for Ascletis' HCV drug

June 13, 2018 9:07 PM UTC

Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) said China's State Drug Administration approved an NDA for Ganovo danoprevir to treat HCV. The company intends to launch the product next quarter, according to its website. Ascletis said the drug is the first domestically developed direct-acting antiviral agent.

Last month, Ascletis became the first biotech to apply for an IPO on the new biotech chapter of the Hong Kong Exchanges and Clearing Ltd. (HKEX) (see BioCentury, May 11)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Target Profiles

HCV NS3/4A protease complex